BiBB receives patent approval for EndoDrill in India

The cancer diagnostics company BiBBInstruments AB ("BiBB" or the "Company"), the developer of the world's first market-cleared electric-driven biopsy instrument for endoscopy, announces today that the Indian Patent Office has granted the first patent for EndoDrill^®. The patent provides broad protection of the EndoDrill^® system until October 2039.

The approved Indian patent 532933 originates from the patent application IN202127017788 from patent family 1 and protects the EndoDrill^® product series, the world's first market-cleared electric-driven biopsy instrument for endoscopy. BiBB has two additional international patent families for EndoDrill^® that have entered the national/regional phase. In 2023, BiBB received approval of two patents in Europe, and in February 2024, the Japanese Patent Office decided to approve the first patent for EndoDrill^®.

"The first approved patent in India strengthens our global IP portfolio and increases the possibility of a successful future global launch with a partner," says Fredrik Lindblad, CEO of BiBB.

About EndoDrill®

EndoDrill^® biopsy instruments work with precision to take high-quality tissue samples to improve diagnostics for several types of cancer, such as stomach, pancreatic, liver, lung, and bladder cancer. The innovative product technology redefines the growing area of endoscopic ultrasound-guided tissue acquisition for cancer diagnostics. The motorized high-speed rotational EndoDrill^® needle enables high-quality core biopsies, overcoming the limitations of today’s standard manual needles.

In 2023, EndoDrill^® GI, BiBB’s lead product, received market clearance from the US FDA as the first electric-driven biopsy instrument for endoscopy in the USA. At the beginning of 2024, CE certification according to MDR was obtained in Europe for the entire EndoDrill^® product family. The EndoDrill^® system has been designed to be easy to use consisting of a sterile disposable biopsy instrument with an associated drive system.

This is a translation of the Swedish press release. If there should be any discrepancies, the Swedish language version prevails.

For more information about BiBB, please contact:
Fredrik Lindblad, CEO
E-mail: [email protected]
Phone: +46 70 899 94 86
www.bibbinstruments.com

This disclosure contains information that BiBBInstruments AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on April 18, 2024.

About BiBB

The cancer diagnostics company BiBBInstruments AB develops and manufactures EndoDrill^®, a patented product line of electric-driven endoscopic biopsy instruments. The EndoDrill^® instruments take high-quality tissue samples with high precision with the goal of improving the diagnosis of several serious cancers, such as stomach, pancreas, liver, lung, and bladder. The product portfolio is aimed at the global market for ultrasound-guided endoscopic (EUS/EBUS) biopsy instruments, which constitute the most advanced and fast-growing area of endoscopy. BiBB received 510(k) clearance from the US FDA for the lead product EndoDrill^® GI in 2023. At the beginning of 2024, CE marking according to MDR was also obtained for all three product variants: EndoDrill^® GI, EndoDrill^® EBUS and EndoDrill^® URO. Thus EndoDrill^® is the first cleared electric endoscopic biopsy system in both the US and Europe. The EndoDrill^® system includes sterile disposable biopsy instruments with associated drive system. The company was founded in 2013 by Dr. Charles Walther, cancer researcher at Lund University and senior consultant in clinical pathology at Skåne University Hospital in Lund. BiBBInstruments is based at Medicon Village in Lund and the BiBBInstruments share (ticker: BIBB) is listed on Spotlight Stock Market.